150 related articles for article (PubMed ID: 24007745)
1. New hope for relapsed and refractory multiple myeloma.
Leleu X
Lancet Oncol; 2013 Oct; 14(11):1028-1029. PubMed ID: 24007745
[No Abstract] [Full Text] [Related]
2. Intra-patient dose escalation of panobinostat in patients with relapsed/refractory multiple myeloma.
Isoda A; Ishikawa T; Miyazawa Y; Mihara M; Matsumoto M; Sawamura M
Leuk Lymphoma; 2018 May; 59(5):1277-1278. PubMed ID: 28874073
[No Abstract] [Full Text] [Related]
3. Histone deacetylase inhibitors in multiple myeloma.
Pratt G
Lancet Oncol; 2013 Oct; 14(11):1038-1039. PubMed ID: 24055413
[No Abstract] [Full Text] [Related]
4. Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma.
Kraut EH; Young D; Farag S; James AG; Solove RJ
Leuk Res; 2005 Oct; 29(10):1233-4. PubMed ID: 16111541
[No Abstract] [Full Text] [Related]
5. Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the 'Rete Ematologica Pugliese E Basilicata'.
Mele G; Pastore D; Di Renzo N; Fragasso A; Guarini A; Mazza P; Musto P; Pavone V; Tarantini G; Curci P; Falcone AP; Mele A; Miccolis MR; Palazzo G; Palumbo G; Quinto AM; Reddiconto G; Rizzi R; Cascavilla N; Specchia G; Capalbo SF
Leuk Lymphoma; 2019 Dec; 60(14):3565-3568. PubMed ID: 31286780
[No Abstract] [Full Text] [Related]
6. A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Cavenagh J; Oakervee H; Baetiong-Caguioa P; Davies F; Gharibo M; Rabin N; Kurman M; Novak B; Shiraishi N; Nakashima D; Akinaga S; Yong K
Br J Cancer; 2017 Oct; 117(9):1295-1302. PubMed ID: 28873084
[TBL] [Abstract][Full Text] [Related]
7. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
Moreau P; Kumar SK; San Miguel J; Davies F; Zamagni E; Bahlis N; Ludwig H; Mikhael J; Terpos E; Schjesvold F; Martin T; Yong K; Durie BGM; Facon T; Jurczyszyn A; Sidana S; Raje N; van de Donk N; Lonial S; Cavo M; Kristinsson SY; Lentzsch S; Hajek R; Anderson KC; João C; Einsele H; Sonneveld P; Engelhardt M; Fonseca R; Vangsted A; Weisel K; Baz R; Hungria V; Berdeja JG; Leal da Costa F; Maiolino A; Waage A; Vesole DH; Ocio EM; Quach H; Driessen C; Bladé J; Leleu X; Riva E; Bergsagel PL; Hou J; Chng WJ; Mellqvist UH; Dytfeld D; Harousseau JL; Goldschmidt H; Laubach J; Munshi NC; Gay F; Beksac M; Costa LJ; Kaiser M; Hari P; Boccadoro M; Usmani SZ; Zweegman S; Holstein S; Sezer O; Harrison S; Nahi H; Cook G; Mateos MV; Rajkumar SV; Dimopoulos MA; Richardson PG
Lancet Oncol; 2021 Mar; 22(3):e105-e118. PubMed ID: 33662288
[TBL] [Abstract][Full Text] [Related]
8. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
Richardson PG; Laubach J; Mitsiades C; Schlossman RL; Doss D; Colson K; McKenney ML; Noonan K; Warren DL; Ghobrial IM; Munshi NC; Anderson K
Oncology (Williston Park); 2010 Mar; 24(3 Suppl 2):22-9. PubMed ID: 20518367
[TBL] [Abstract][Full Text] [Related]
9. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.
Chng WJ; Goldschmidt H; Dimopoulos MA; Moreau P; Joshua D; Palumbo A; Facon T; Ludwig H; Pour L; Niesvizky R; Oriol A; Rosiñol L; Suvorov A; Gaidano G; Pika T; Weisel K; Goranova-Marinova V; Gillenwater HH; Mohamed N; Feng S; Aggarwal S; Hájek R
Leukemia; 2017 Jun; 31(6):1368-1374. PubMed ID: 28025582
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.
Bahlis NJ; McCafferty-Grad J; Jordan-McMurry I; Neil J; Reis I; Kharfan-Dabaja M; Eckman J; Goodman M; Fernandez HF; Boise LH; Lee KP
Clin Cancer Res; 2002 Dec; 8(12):3658-68. PubMed ID: 12473574
[TBL] [Abstract][Full Text] [Related]
11. Management of Relapsed and Refractory Hodgkin Lymphoma in 2018.
Rutherford SC; Leonard JP
JAMA Oncol; 2018 Aug; 4(8):1120-1121. PubMed ID: 30003234
[No Abstract] [Full Text] [Related]
12. Relapsed and refractory multiple myeloma: new therapeutic strategies.
Gentili S; Lonial S
Hematol Oncol Clin North Am; 2014 Oct; 28(5):861-90. PubMed ID: 25212887
[TBL] [Abstract][Full Text] [Related]
13. "Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese".
Mele G; Melpignano A; Quarta G; Palumbo G; Capalbo S; Falcone A; Cascavilla N; Palazzo G; Mazza P; Iannitto E; Curci P; Rizzi R; Specchia G; Rossini B; Pavone V; Ria R; Vacca A; Buquicchio C; Tarantini G; Minoia C; Guarini A; Ditonno P; Polimeno G; Reddiconto G; Di Renzo N
Leuk Res; 2015 Mar; 39(3):279-83. PubMed ID: 25636354
[TBL] [Abstract][Full Text] [Related]
14. A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.
Shah JJ; Kaufman JL; Zonder JA; Cohen AD; Bensinger WI; Hilder BW; Rush SA; Walker DH; Tunquist BJ; Litwiler KS; Ptaszynski M; Orlowski RZ; Lonial S
Cancer; 2017 Dec; 123(23):4617-4630. PubMed ID: 28817190
[TBL] [Abstract][Full Text] [Related]
15. Management of patients with relapsed/refractory metastatic colorectal cancer.
Grothey A
Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):14-16. PubMed ID: 31730591
[No Abstract] [Full Text] [Related]
16. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
Dimopoulos M; Siegel DS; Lonial S; Qi J; Hajek R; Facon T; Rosinol L; Williams C; Blacklock H; Goldschmidt H; Hungria V; Spencer A; Palumbo A; Graef T; Eid JE; Houp J; Sun L; Vuocolo S; Anderson KC
Lancet Oncol; 2013 Oct; 14(11):1129-1140. PubMed ID: 24055414
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
Palumbo A; Larocca A; Falco P; Sanpaolo G; Falcone AP; Federico V; Canepa L; Crugnola M; Genuardi M; Magarotto V; Petrucci MT; Boccadoro M
Leukemia; 2010 May; 24(5):1037-42. PubMed ID: 20376079
[TBL] [Abstract][Full Text] [Related]
18. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712
[TBL] [Abstract][Full Text] [Related]
19. [Daratumumab for multiple myeloma].
Croizier C; Bailly S
Bull Cancer; 2018 Nov; 105(11):985-991. PubMed ID: 30430991
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.
Popat R; Plesner T; Davies F; Cook G; Cook M; Elliott P; Jacobson E; Gumbleton T; Oakervee H; Cavenagh J
Br J Haematol; 2013 Mar; 160(5):714-7. PubMed ID: 23205612
[No Abstract] [Full Text] [Related]
[Next] [New Search]
